Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia…
AbbVie's VUITY (pilocarpine hydrochloride ophthalmic solution) Overview AbbVie's VUITY (pilocarpine hydrochloride ophthalmic solution) Overview VUITY, developed by Allergan (now part of AbbVie), is a 1.25% pilocarpine hydrochloride ophthalmic solution designed to treat presbyopia in adults. It acts as a cholinergic muscarinic receptor agonist and comes as a sterile, isotonic, colorless solution. The active ingredient, pilocarpine hydrochloride, stimulates muscarinic receptors in smooth...
PR Newswire
26/03/2025
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market…
Spark Therapeutics/Novartis' LUXTURNA (AAV2-hRPE65v2; voretigene neparvovec) Overview Spark Therapeutics/Novartis' LUXTURNA (AAV2-hRPE65v2; voretigene neparvovec) Overview LUXTURNA (voretigene neparvovec-rzyl, AAV2-hRPE65v2) is a one-time gene therapy designed to treat vision loss caused by mutations in both copies of the RPE65 gene. It works by delivering a functional copy of the RPE65 gene to replace the faulty one, helping to restore vision. The therapy is administered as a single...
PR Newswire
26/03/2025
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual…
About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and…
PR Newswire
26/03/2025
Global Surgical Equipment Market Expected to Reach USD 56.6 Billion by 2029
The report examines the leading companies, technology trends, market dynamics, and regional trends in the surgical equipment market. The report also examines the impact of COVID-19 on the market and the supply chain, taking into consideration economic factors such as healthcare spending and medical tourism. It covers the use of emerging technologies such as AI and machine learning in surgeries. The market is segmented by usability (disposable and reusable), product category, technology, end user…
PR Newswire
26/03/2025
Assisted Reproductive Technology Market worth US$6.02 Billion by 2030 with 7.0%…
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91934243 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91934243 Browse in-depth TOC on "Assisted Reproductive Technology Market" 200 - Tables 100 - Figures 300 - Pages By Based on type,Equipment maintains the largest market share in the assisted reproductive technology (ART) market because they are at the forefront of fertility treatment and because...
PR Newswire
26/03/2025
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising…
The therapy plays a critical role in treating relapsed and refractory hematologic cancers. In the U.S., hematologic cancers such as leukemia, lymphoma, and myeloma are diagnosed approximately every three minutes, highlighting an urgent need for innovative treatments. With government support and favorable reimbursement policies, the eligibility of hematologic cancer patients for CAR T-cell therapy increased from 2.7% in 2017 to 3.9% in 2023. Additionally, ongoing research focuses on expanding…
PR Newswire
26/03/2025
Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to…
Adding ARMMs to the company's eTurna® LNP delivery platform greatly expands the reach of Turn Bio's ERA® technology, which uses mRNA to produce proteins that translate the cellular epigenome to restore function and fight conditions caused by aging. Adding ARMMs to the company's eTurna® LNP delivery platform greatly expands the reach of Turn Bio's ERA® technology, which uses mRNA to produce proteins that translate the cellular epigenome to restore function and fight conditions caused by aging...
PR Newswire
26/03/2025
Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary…
Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of directors to carry out a share capital increase of NOK 0.70 through the issuance of seven (7) new shares in the Company in order to achieve a desirable ratio for the reverse share split.The Company has received the following notification of a transaction made by a close associate of a primary insider: Radforsk...
Nasdaq GlobeNewswire
26/03/2025
Homestyler Aims to Accelerate Global Expansion and Innovation Following the…
Homestyler shared AI-driven solutions to address the various pain points faced by three distinct groups: Homestyler shared AI-driven solutions to address the various pain points faced by three distinct groups: AI-Powered Innovation for the Future of Home Design Committed to solving space design challenges for professionals and enthusiasts alike, Homestyler continues to push the boundaries of AI-driven efficiency. As part of its 2025 strategy, the company will focus on three key areas:...
PR Newswire
26/03/2025
Lundbeck held its Annual General Meeting on 26 March 2025 at the company's…
The Remuneration Report for 2024 was approved in the advisory vote. The Remuneration Report for 2024 was approved in the advisory vote. Dorothea Wenzel, Lene Skole-Sørensen,Lars Erik Holmqvist,Jeffrey Berkowitz,Santiago Arroyo, andJakob Riiswere re-elected to the Board of Directors.Lars Greenwas elected as a new member of the Board of Directors. The Board of Directors of Lundbeck will hereafter comprise: Immediately after the general meeting, the Board of Directors...
PR Newswire
26/03/2025
Supira Medical Secures $120M Oversubscribed Series E Financing and Completes…
Additionally, Supira welcomes Dr. Christopher Shen, Partner, Novo Holdings US to its Board of Directors. "We believe there is a massive unmet need for next-generation ventricular support devices to promote myocardial recovery and improve peripheral organ perfusion in HRPCI and CS patients," stated Dr. Shen. "The Supira team has built a strong clinical foundation to further validate their advanced low-profile, high flow technology platform in two important segments of…
PR Newswire
26/03/2025
Lutris Pharma to Present at the American Association for Cancer Research Annual…
Presentation Details: Presentation Details: About EGFR Inhibitor-Induced RashEGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin. The EGFR signaling pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various...
PR Newswire
26/03/2025
Novo Holdings participates in €23 million Series A for Tribune Therapeutics to…
Through a Pioneer Innovator Grant, the Novo Nordisk Foundation – whose assets Novo Holdings manages – partially funded scientific discoveries at the Oslo University Hospital by Professor Håvard Attramadal and Ole J. Kaasbøll that led to Tribune's formation. The Pioneer Innovator grant programme is designed to advance science-based discoveries in sustainability and health by funding experiments and activities that push ideas toward proof-of-concept and beyond, in line with Novo Nordisk…
PR Newswire
26/03/2025
Beauty Supplements Market worth $5.76 billion by 2030- Exclusive Report by…
Browse in-depth TOC on "Beauty Supplements Market" Browse in-depth TOC on "Beauty Supplements Market" 250 – Tables70 – Figures350 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=165507335 The powder segment holds the significant market share in the beauty supplements segment. Powdered beauty supplements are universally favored due to their high bioavailability, adaptive dosing, and convenience of consumption. They have a...
PR Newswire
26/03/2025
Zymeworks Announces Participation in Upcoming Investor Conferences
Needham 24 thAnnual Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 8 at 9:30 am Eastern Time (ET).Stifel 2025 Virtual Targeted Oncology Forum: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on April 9 at 12:30 pm ET.About Zymeworks Inc.Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of...
Nasdaq GlobeNewswire
26/03/2025
Alma introduces Alma Harmony, a state-of-the-art aesthetic platform for…
Alma Harmony takes a huge leap forward in patient personalization. The new evolution is powered by the five of the most in-demand technologies, brilliantly integrated to provide a comprehensive range of treatments for almost any indication or skin type: the Q-Switch Laser stimulates collagen and treats pigmentation by targeting dermal layers, the Fractional Ablative laser creates pixel-sized perforations in the skin, inducing rejuvenation while preserving surrounding tissues for quicker…
PR Newswire
26/03/2025
SIBIONICS GS3: The World's Thinnest CGM Debuts at ATTD 2025
With its ultra-compact design and 3-second activation, GS3 quickly became a highlight at ATTD 2025 with its revolutionary thinness of just 2.9mm, comparable to a small coin. It offers: With its ultra-compact design and 3-second activation, GS3 quickly became a highlight at ATTD 2025 with itsrevolutionary thinness of just 2.9mm, comparable to a small coin. It offers: In-Depth Exploration of CGM & CKM in Clinical Applications At ATTD 2025, SIBIONICS hosted the SIBIONICS Symposium,...
PR Newswire
26/03/2025
NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC…
The adopted wording for the newly extended indication is: The adopted wording for the newly extended indication is: "Slenyto® is indicated for the treatment of insomnia: "We recognise there is significant unmet need and high demand for addressing sleep maintenance and duration as well as sleep initiation difficulties of children withADHD,who suffer from impaired sleep.The European Commission (EC) granted marketing authorization (MA) of Slenyto ®for insomnia in children with ADHD...
PR Newswire
26/03/2025
Procare Health released results from their latest clinical trial, Paloma 2…
MADRID, March 25, 2025 /PRNewswire/ -- Key Findings and Scientific Evidence MADRID , March 25, 2025 /PRNewswire/ --Key Findings and Scientific Evidence ThePaloma 2clinical trial, conducted in19 Spanish hospitals, involved164 womenwith an average age of41.13 years. All participants tested positive forhigh-risk HPVand presented with low-grade cervical lesions. The trial compared two groups: one received intensive treatment withPapilocare®, while the other...
PR Newswire
26/03/2025
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of…
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has...
Nasdaq GlobeNewswire
26/03/2025
Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development…
During his thirteen years at Pieris, Shane played a pivotal role developing its diverse pipeline of clinical programs in immuno-oncology and respiratory diseases – progressing nine programs into the clinic. Prior to that he was Director of Research at AIM-listed Fusion Antibodies, building out its research team and establishing its technology platform. With over 60 intellectual property rights to his name, he is a recognized leader in drug development and a regular reviewer for prominent…
PR Newswire
26/03/2025
Photocure appoints Jane Healy as Vice President and General Manager EMEA
In her most recent role, Jane Healy was VP EMEA for the Peripheral Interventions Division for Boston Scientific, responsible for driving the growth strategy for the region. She brings a blend of strong commercial acumen, results orientation and a passion for enabling and driving results through her teams. Jane Healy holds a BA (Hons) in Modern Languages from Cambridge University and she speaks English, French, German and Italian. In her most recent role,Jane Healywas VP EMEA for the...
PR Newswire
26/03/2025
Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for…
The pre-IND meeting provided an opportunity for the Company to discuss its Investigational New Drug (IND) development plan and receive FDA guidance on nonclinical and clinical study requirements for its new drug candidate PTX-252. In the written response from the Division of Hematologic Malignancies, the FDA provided constructive feedback and expressed support for Pleco's proposed development strategy.PTX-252 is a small molecule designed to remove toxic heavy metals from the tumour...
Nasdaq GlobeNewswire
26/03/2025
FDA Issues Nyxoah an Approvable Letter for its Genio® System
INSIDE INFORMATION REGULATED INFORMATIONFDA Issues Nyxoah an Approvable Letter for its Genio® SystemMont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company's Pre-Market...
Nasdaq GlobeNewswire
26/03/2025
Altri Comunicati
